Tokyo Tape
Sign in
← H.U. Group Holdings

Quarterly report · Q2

4544.TEDINET S100PJXC
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥134.1bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥272.9bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥133.7bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥17.7bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥27.0bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥17.8bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥47.4bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥26.7bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥20.7bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥25.1bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥15.6bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥29.6bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥19.5bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥15.6bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥19.5bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥285.9bnat 2022-09-30Cons.Assets
Total assets¥286.6bnat 2022-03-31Cons.Assets
Total assets¥271.5bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥128.6bnat 2022-09-30Cons.Liabilities
Total liabilities¥146.4bnat 2022-03-31Cons.Liabilities
Net assets / equity¥157.3bnat 2022-09-30Cons.Net assets
Net assets / equity¥140.2bnat 2022-03-31Cons.Net assets
Net assets / equity¥130.9bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥37.3bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥46.5bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥37.3bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥46.5bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥41.8bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥43.0bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥15.8bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥55.2bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥20.9bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥18.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥30.9bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥12.8bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥7.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥21.7bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥9.3bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥273.422022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥175.172022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥519.552021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥342.232021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥195.932021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥273.382022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥519.422021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥342.12021-04-01 → 2021-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio55.0%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio48.9%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio48.2%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥5.1bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥5.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥1.5bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥85.1bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥85.0bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥83m
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.9bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥40.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥35.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥5.0bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥15.7bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2022-04-01 → 2022-09-30¥13.8bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2022-04-01 → 2022-09-30¥13.8bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥10m
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2022-04-01 → 2022-09-30¥604m
—segment totalrevenue2022-04-01 → 2022-09-30¥139.2bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥134.1bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥5.1bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥19.2bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥4.9bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥4.9bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥746m
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥88.8bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥88.8bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥33m
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥14.7bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥35.0bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥30.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥4.8bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥12.0bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2021-04-01 → 2021-09-30¥14.7bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2021-04-01 → 2021-09-30¥14.7bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥10m
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.0bn
—segment totalrevenue2021-04-01 → 2021-09-30¥138.6bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥133.7bn
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥4.9bn
—segment totalsegment profit2021-04-01 → 2021-09-30¥27.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 532
ItemContextValueUnit
Provision for bonusesPrior1YearInstant6870000000JPY
Provision for bonusesCurrentQuarterInstant4957000000JPY
Other clPrior1YearInstant17174000000JPY
Other clCurrentQuarterInstant12215000000JPY
Current liabilitiesPrior1YearInstant70755000000JPY
Current liabilitiesCurrentQuarterInstant57292000000JPY
Bonds payablePrior1YearInstant35000000000JPY
Bonds payableCurrentQuarterInstant35000000000JPY
Long term loans payablePrior1YearInstant18700000000JPY
Long term loans payableCurrentQuarterInstant15000000000JPY
Net defined benefit liabilityPrior1YearInstant5470000000JPY
Net defined benefit liabilityCurrentQuarterInstant5548000000JPY
Asset retirement obligations nclPrior1YearInstant1046000000JPY
Asset retirement obligations nclCurrentQuarterInstant1178000000JPY
Provision for share based remuneration nclPrior1YearInstant572000000JPY
Provision for share based remuneration nclCurrentQuarterInstant694000000JPY
Provision for compensation loss nclPrior1YearInstant709000000JPY
Provision for compensation loss nclCurrentQuarterInstant610000000JPY
Provision for loss on guaranteesPrior1YearInstant1414000000JPY
Provision for loss on guaranteesCurrentQuarterInstant840000000JPY
Other nclPrior1YearInstant12739000000JPY
Other nclCurrentQuarterInstant12468000000JPY
Noncurrent liabilitiesPrior1YearInstant75653000000JPY
Noncurrent liabilitiesCurrentQuarterInstant71339000000JPY
LiabilitiesPrior1YearInstant146408000000JPY
LiabilitiesCurrentQuarterInstant128632000000JPY
Capital stockPrior1YearInstant9231000000JPY
Capital stockCurrentQuarterInstant9271000000JPY
Capital surplusPrior1YearInstant24953000000JPY
Capital surplusCurrentQuarterInstant24993000000JPY
Retained earningsPrior1YearInstant103957000000JPY
Retained earningsCurrentQuarterInstant115908000000JPY
Treasury stockPrior1YearInstant-2081000000JPY
Treasury stockCurrentQuarterInstant-2059000000JPY
Shareholders equityPrior1YearInstant136060000000JPY
Shareholders equityCurrentQuarterInstant148113000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant1620000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant228000000JPY
Foreign currency translation adjustmentPrior1YearInstant3997000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant10361000000JPY
Remeasurements of defined benefit plansPrior1YearInstant-1573000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant-1471000000JPY
Valuation and translation adjustmentsPrior1YearInstant4045000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant9118000000JPY
Subscription rights to sharesPrior1YearInstant72000000JPY
Subscription rights to sharesCurrentQuarterInstant70000000JPY
Net assetsPrior1YearInstant140178000000JPY
Net assetsCurrentQuarterInstant157301000000JPY
Liabilities and net assetsPrior1YearInstant286587000000JPY
Liabilities and net assetsCurrentQuarterInstant285933000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass